No Data
No Data
Astellas Pharma: Confirmation Letter
Astellas Pharma: Securities Report - 19th Period (April 1, 2023 - March 31, 2024)
Helios - year-to-date high, signing a license agreement with Astellas Pharma subsidiary.
Hit a new high since the beginning of the year. Astellas Pharma announced that it has signed a license agreement with a subsidiary and a method for producing retinal pigment epithelial (RPE) cells, which is considered a good material. The company has signed a license agreement to non-exclusively license patents on RPE cell manufacturing and purification methods held by the company in countries other than Japan worldwide. They will receive $3 million as a lump sum payment at the time of the contract signing. Furthermore, products developed and manufactured using this patent are authorized in the United States.
Steady, with buying on dips prevailing despite a lack of clues.
[Emerging markets individual stock strategy] Today's emerging market is expected to show a positive trend. The US stock market on June 19th was closed for Juneteenth, a holiday commemorating the abolition of slavery. Among the major European stock indices, the German DAX fell 0.35%, the French CAC40 fell 0.77%, and the British FTSE TM100 rose 0.17%. Today's emerging market is likely to be dominated by buying. With the US stock market closed yesterday and the major European stock indices showing mixed results, it is difficult to find clues. Emerging markets rose 5.
Pay attention to Iwata-san and Interact.
The US stock market was closed on Juneteenth. Major European equity indices saw Germany's DAX drop by 0.35%, France's CAC 40 drop by 0.77%, and the UK's FTSE TM100 rise by 0.17%. The exchange rate was 1 dollar = 157.90-158.00 yen. At the Tokyo market today, Shukai Shigeki <6358> announced that it recorded investment securities sales proceeds of 288 million yen as special profits for the first quarter of the fiscal year 25 ending in March, and implemented a share buyback and purchase of up to 1.19% of the issued shares.
Helios, Bright Pass and others.
<130A> Takeda Pharmaceutical Industries <4502> achieved milestones in joint drug discovery research with VIS <3815> Media lowers financial estimates for the current period, expecting an operating loss of 106 million yen instead of the previous estimation of a 60 million yen loss, and discontinues the year-end dividend, establishing a new shareholder benefit program. A medium-term management plan for the fiscal year ending August 2026 has been formulated, with an operating profit goal of 250 million yen for the fiscal year ending August 2026. <4593> Helios Astellas Pharma <4503> signs a license agreement regarding manufacturing methods for RPE cells.
No Data